RnR Market Research

Leber Congenital Amaurosis Therapeutic Pipeline Review H1 2015 Market Research Report

RnRMarketResearch.com adds “Leber Congenital Amaurosis (LCA) – Pipeline Review, H1 2015” to its store. The report provides an overview of the Leber Congenital Amaurosis (LCA)’s therapeutic pipeline.


Dallas, TX -- (SBWIRE) -- 06/02/2015 -- The report "Leber Congenital Amaurosis (LCA) – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.. Complete report on H1 2015 pipeline review of Leber Congenital Amaurosis (LCA) with 22 market data tables and 12 figures, spread across 52 pages is available at http://www.rnrmarketresearch.com/leber-congenital-amaurosis-lca-pipeline-review-h1-2015-market-report.html

Companies discussed in this Leber Congenital Amaurosis (LCA) – Pipeline Review, H1 2015 report include BBB Therapeutics B.V., ProQR Therapeutics N.V., QLT Inc., Spark Therapeutics, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1, QLT-091001, QR-110, rAAV2-CB-hRPE65, Small Molecules for Inherited Retinal Diseases, SPK-RPE-65, tgAAG-76.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=386030
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases: Dec 05, 2014: QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision; Nov 06, 2014: Spark Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SPK-RPE65; Sep 12, 2014: QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT; Jul 14, 2014: QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations; May 08, 2014: Spark Therapeutics Scientific Advisor to Deliver Keynote at the Association for Research in Vision and Ophthalmology's 2014 Annual Meeting ; Feb 27, 2014: QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65; Jan 14, 2014: Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness.

Explore more reports on Ophthalmology therapeutics at